Technical Development observational study for Musculoskeletal (MSK) Magnetic Resonance Imaging
The purpose of this research study is to find new MRI techniques and new ways to identify and treat various diseases and syndromes. This study will last about three years and will involve 1 or more visits, depending on your availability and interest. While in this study you will be asked to lie down on an MRI scanner and have a piece of your body scanned for about 1 hour.
Technical Development Observational Study for Novel MRI Acquisition and Reconstruction Strategies
The Department of Radiology develops new MRI techniques. The hope is to better find the presence of disease or injury earlier than the techniques that are used now. The objective of this study is to determine whether the newly developed MRI techniques can provide this information.
Technical Software Development on Ultra-Low Field MRI
The objective of this study is to develop and evaluate software techniques that promote the medical usefulness of a smaller, portable, low-field strength MRI. The study will examine if this new machine can produce images with meaningful anatomic information about the brain/head that (a) are useful in diagnosing illness and (b) prove MRI to be an affordable screening device.
Tenex Procedure for Knee Sprains & Strains | NYU Langone Health
NYU Langone doctors offer the minimally invasive Tenex procedure to help with the healing process in people with knee sprains or strains.
Testicular Cancer | NYU Langone Health
Perlmutter Cancer Center urologists, surgeons, and oncologists work together to diagnose and treat testicular cancer.
Testing Offered at the Voice Center | NYU Langone Health
At NYU Langone’s Voice Center, we offer a range of specialized tests for voice, swallowing, and airway conditions.
Tests for Infertility | NYU Langone Health
At the NYU Langone Fertility Center, experts can perform a variety of tests to assess your fertility potential.
Tetralogy of Fallot in Children | NYU Langone Health
Doctors at the Pediatric Congenital Heart Program at Hassenfeld Children’s Hospital at NYU Langone treat children who have tetralogy of Fallot.
TH-189: A Phase 2 Study of Nivolumab plus Ramucirumab in Patients with Recurrent Advanced Metastatic Non-Small Cell Lung Carcinoma
This study will involve patients who have been diagnosed with non-small cell lung cancer, regardless of the specific type. These patients should have previously received immunotherapy but their disease has gotten worse after one round of treatment using either immunotherapy alone or a combination of immunotherapy and chemotherapy. Patients will receive two medications called Nivolumab and Ramucirumab. These medications will be given through a vein, and the dose will depend on the patient's body weight. The treatment will be given on the first day and the fifteenth day of each 28-day cycle. To see how well the treatment is working, patients will have regular check-ups every two cycles. They will undergo a CT scan to see how the disease is responding to the treatment. The check-ups will be done within a week before or after the scheduled date. The treatment will continue until the disease gets worse, the side effects become too severe, or the patient decides to stop the treatment. The patients will be followed up until they pass away to monitor their condition and gather more information.
The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD) A Double-Blinded Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
The purpose of the study is to determine if the invasive disease-free survival (iDFS) with T-DM1 and tucatinib is superior to the iDFS in the control arm (T-DM1 + placebo) when administered to high risk patients with HER2-positive breast cancer and residual disease after neoadjuvant HER2-directed therapy. We want to evaluate whether treatment with tucatinib plus T-DM1 compared to treatment with T-DM1 alone (T-DM1 plus placebo) improves the following: overall survival (OS), breast cancer free survival (BCFS), distant recurrence-free survival (DRFS), disease-free survival (DFS), brain metastases-free survival (BMFS). We want to know whether treatment with tucatinib plus T-DM1 compared to treatment with T-DM1 alone (T-DM1 plus placebo) reduces the incidence of brain metastases.